Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 11/2010

01-09-2010 | Review

Fibromyalgia and nutrition, what do we know?

Authors: Laura-Isabel Arranz, Miguel-Ángel Canela, Magda Rafecas

Published in: Rheumatology International | Issue 11/2010

Login to get access

Abstract

Many people suffer from fibromyalgia (FM) without an effective treatment. They do not have a good quality of life and cannot maintain normal daily activity. Among the different hypotheses for its ethiopathophysiology, oxidative stress is one of the possibilities. Non-scientific information addressed to patients regarding the benefits of nutrition is widely available, and they are used to trying non-evidenced strategies. The aim of this paper is to find out what we know right now from scientific studies regarding fibromyalgia disease and nutritional status, diets and food supplements. A systematic search has been performed on Medline with a wide range of terms about these nutritional issues. The search has been made during 2009, for articles published between 1998 and 2008. Target population: people suffering from FM. Vegetarian diets could have some beneficial effects probably due to the increase in antioxidant intake. There is a high prevalence of obesity and overweight in patients, and weight control seems to be an effective tool to improve the symptoms. Some nutritional deficiencies have been described, it is not clear whether they are directly related to this disease or not. About the usefulness of some food supplements we found very little data, and it seems that more studies are needed to prove which ones could be of help. Dietary advice is necessary to these patients to improve their diets and maintain normal weight. It would be interesting to investigate more in the field of nutrition and FM to reveal any possible relationships.
Literature
1.
Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 33:160–172CrossRefPubMed
2.
Weir P, Harlan G, Nkoy F et al (2006) The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th revision codes. J Clin Rheumatol 12:124–128CrossRefPubMed
3.
Maquet D, Croisier JL, Crielaard JM (2000) Fibromyalgia in the year. Rev Med Liege 55(11):991–997PubMed
4.
Lawrence R, Helmick C, Arnett F et al (1998) Estimates of the prevalence of artritis and selected músculoskeletal disorders in the United States. Artritis Rheum 41:778–799CrossRef
5.
Wolfe F, Ross K, Anderson J et al (1995) The prevalence and characteristics of fibromyalgia in the general population. Artritis Rheum 38:19–28CrossRef
6.
White KP, Speedchley M, Harth M et al (1999) The London fibromyalgia epidemiology study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 26(7):1570–1576PubMed
7.
White KP, Harth M (2001) Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 5(4):320–329CrossRefPubMed
8.
Valverde M, Juan A, Ribas B et al (2000) Prevalencia de la fibromialgia en la población española. Estudio EPISER 2000. Rev Esp Reumatol 27(5):157
9.
Carmona L, Ballina J, Gabriel R et al (2001) EPISER study group. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 60(11):1040–1045
10.
Mas AJ, Carmona L, Valverde M et al (2008) EPISER study group. Prevalence and impact of fibromyalgia on function and quality of life in individuals from the general population results from a nationwide study in Spain. Clin Exp Rheumatol 26(4):519–526
11.
Gamero F, Gabriel R, Carbonell J et al (2005) Pain in Spanish rheumatology outpatient offices: EPIDOR epidemiological study. Rev Clin Esp 205:157–163CrossRef
12.
Salaffi F, De Angelis R, Gras W et al (2005) Pain prevalence, investigation group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 23(6):819–828
13.
Bannwarth B, Blotman F, Roué-Le Lay K et al (2008) Fibromyalgia síndrome in the general population of France: a prevalence study. Joint Bone Spine 24. [Epub ahead of print]
14.
Felson DT (2008) Comparing the prevalence of rheumatic diseases in China with the rest of the world. Editorial. Arthritis Res Ther 10:106
15.
Eisinger J, Plantamura A, Marie PA et al (1994) Selenium and magnesium status in fibromyalgia. Magnes Res 7(3–4):285–288PubMed
16.
Reinhard P, Schweinsberg F, Wernet D et al (1998) Selenium status in fibromyalgia. Toxicol Lett 96–97:177–180CrossRefPubMed
17.
Ozgocmen S, Ozyurt H, Sogut S et al (2006) Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia etiologic and therapeutic concerns. Rheumatol Int 26:598–603CrossRefPubMed
18.
Bagis S, Tamer L, Sahin G et al (2005) Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Reumatol Int 25:188–190CrossRef
19.
Altindag O, Celik H (2006) Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. Redox Rep 11(3):131–135CrossRefPubMed
20.
Pieczenik SR, Neustadt J (2007) Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 83:84–92CrossRefPubMed
21.
Ozgocmen S, Ozyurt H, Sogut S et al (2006) Current concepts in the pathophysilogy of fibromyalgia: the potential role of oxidative stress and nitric oxide. Reumatol Int 26:585–597CrossRef
22.
Pall ML (2001) Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. Med Hypotheses 57(2):139–145CrossRefPubMed
23.
Hänninen O, Kaartinen K, Rauma AL et al (2000) Antioxidants in vegan diet and rheumatic disorders. Toxicology 155:45–53CrossRefPubMed
24.
Donaldson MS, Speight N, Loomis S (2001) Fibromyalgia syndrome improved using a mostly raw vegetarian diet: an observational study. BMC Complement Altern Med 1:7CrossRefPubMed
25.
Vecchiet J, Cipollone F, Falasca K et al (2003) Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett 335(3):151–154CrossRefPubMed
26.
Kennedy G, Spence VA, McLaren M et al (2005) Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med 39:584–589CrossRefPubMed
27.
Richards RS, Wang L, Jelinek H (2007) Erythrocyte oxidative damage in chronic fatigue syndrome. Arch Med Res 38:94–98CrossRefPubMed
28.
Zhang Z, Cherryholmes G, Mao A et al (2008) High plasma levels of MCP-1 and Eotaxin provide evidence for an immunological basis of fibromyalgia. Exp Biol Med 2333:1171–1180
29.
Wallace DJ, Linker-Israeli M, Hallegua D et al (2001) Cytokines paly an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 40:74–749CrossRef
30.
Wallace DJ (2006) Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des 12(1):17–22CrossRefPubMed
31.
Chakrabarty S, Zoorob R (2007) Fibromyalgia. Am Fam Physician 15; 76(2):247–254
32.
Carville SF, Arendt-Nielsen S, Bliddal H et al (2008) EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 67:536–541CrossRefPubMed
33.
Perrot S, Dickenson AH, Bennett RM (2008) Fibromyalgia: harmonizing science with clinical practice considerations. Pain Practice 8(3):177–189CrossRefPubMed
34.
Abeles M, Solitar BM, Pillinger MH et al (2008) Update on fibromyalgia therapy. Am J Med 121:555–561CrossRefPubMed
35.
Goldenberg DL, Burckhardt C, Crofford L (2004) Management of fibromyalgia síndrome. JAMA 292(19):2388–2395CrossRefPubMed
36.
Nishishinya MB, Rivera J, Alegre C et al (2006) Intervenciones no farmacológicas y tratamientos alternativos en la fibromialgia. Med Clin 12(8):295–299
37.
Kaartinen K, Lami K, Hypen M et al (2000) Vegan diet alleviates fibromyalgia symptoms. Scand J Rheumatol 29(5):308–313CrossRefPubMed
38.
Bennet RM (2002) A raw vegetarian diet for patients with fibromyalgia. Curr Rheumatol Rep 4(4):284
39.
Azad KA, Alam MN, Hag SA et al (2000) Vegetarian diet en the treatment of fibromyalgia. Bangladesh Med Res Counc Bull 26(2):41–47PubMed
40.
Michalsen A, Riegert M, Lüdtke R et al (2005) Mediterranean diet or extended fasting’s influence on changing the intestinal microflora, immunoglobulin A secretion and clinical outcome in patients with rheumatoid artritis and fibromyalgia: an observational study. BMC Complement Altern Med 5:22CrossRefPubMed
41.
Smith JD, Terpening CM, Schmidt SOF et al (2001) Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. Ann Pharmacother 35:702–706CrossRefPubMed
42.
Geenen R, Janssens EL, Jacobs JWG et al (2004) Dietary glutamate will not affect pain in fibromyalgia. J Rheumatol 31:785–787PubMed
43.
Cairns BE, Svensson P (2005) Dietary glutamate and fibromyalgia. J Rheumatol 32(2):392–393; Author reply 393–394
44.
Cymet TC (2003) A practical approach to fibromyalgia. J Natl Med Assoc 95:278–285PubMed
45.
Arnold LM, Hudson JI, Keck PE et al (2006) Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 67:1219–1225CrossRefPubMed
46.
Javaras KN, Harrison GP, Lalonde JK et al (2008) Co-occurrence of binge eating disorder with psychiatric and medical disorders. J Clin Psychiatry 69:266–273CrossRefPubMed
47.
Bennett RM, Jones J, Turk DC et al (2007) An internet survey of 2, 596 people with fibromyalgia. BMC Musculoskeletal Disorders 8:27CrossRefPubMed
48.
Patucchi E, Fatati G, Puxeddu A et al (2003) Prevalence of fibromyalgia in diabetes mellitus and obesity. Recent Prog Med 94:163–165
49.
Yunus MB, Arslan S, Aldag JC (2002) Relationship between body mass index and fibromyalgia features. Scand J Rheumatol 31:27–31CrossRefPubMed
50.
Mengshoel AM, Haugen M (2001) Health status in fibromyalgia–a followup study. J Rheumatol 28:2085–2089PubMed
51.
Shapiro JR, Anderson DA, Noff-Burg S (2005) A pilot study of the effects of behavioral weight loss treatment on fibromyalgia symptoms. J Psychosom Res 59:275–282CrossRefPubMed
52.
Neumann L, Lerner E, Glazer Y et al (2008) A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life, and physical functioning in fibromyalgia patients. Clin Rheumatol 27(12):1543–1547CrossRefPubMed
53.
Shaver JLF, Wilbur J, Robinson P et al (2006) Women’s health issues with Fibromyalgia syndrome. J Women’s Health 9(15):1035–1045
54.
Hooper MM, Stellato TA, Hallowell PT et al (2007) Musculoskeletal findings in obese subjects before and after weight loss following bariatric surgery. Int J Obes 31:114–120CrossRef
55.
Ananda A, Caterson I, Sambrook P et al (2008) The impact of obesity on the musculoskeletal system. Int J Obes 32(2):211–222CrossRef
56.
Lowe JC, Yellin J, Honeyman-Lowe G (2006) Female fibromyalgia patients: lower resting metabolic rates than matched healthy controls. Med Sci Monit 12(7):CR282-9
57.
Loevinger B, Muller D, Alonso C et al (2007) Metabolic syndrome in women with chronic pain. Metab Clin Exp 56:87–93PubMed
58.
Verheesen RH, Schweitzer CM (2008) Iodine deficiency, more than cretinism and goiter. Med Hypotheses 71:645–648CrossRefPubMed
59.
Pamuk GE, Pamuk ON, Set T et al (2008) An increased prevalence of fibromyalgia in iron deficiency anemia and thalassemia minor and associated factors. Clin Rheumatol 27:1103–1108CrossRefPubMed
60.
Swezey RL, Adams J (1999) Fibromyalgia: a risk factor for osteoporosis. J Rheumatol 26(12):2642–2644PubMed
61.
Al-Allaf AW, Mole PA, Paterson CR et al (2003) Bone health in patients with fibromyalgia. Rheumatology 42:1202–1206CrossRefPubMed
62.
Plotnikoff GA, Quigley JM (2003) Prevalence of severe hipovitaminosis D in patients with persistent nonspecific musculoskeletal pain. Mayo Clin Proc 78:1463–1470CrossRefPubMed
63.
Block SR (2004) Vitamin D deficiency is not associated with nonspecific musculoskeletal pain syndromes including fibromyalgia. Mayo Clin Proc 79(12):1585–1591CrossRefPubMed
64.
Warner AE, Arnspiger SA (2008) Diffuse musculoskeletal pain is not associated with low vitamin D levels or improved by treatment with vitamin D. J Clin Rheumatol 14(1):12–16CrossRefPubMed
65.
Armstrong DJ, Meenagh GK, Bickle I (2007) Vitamin D deficiency is associated with anxiety and depression in fibromyalgia. Clin Rheumatol 26:551–554CrossRefPubMed
66.
Mouyis M, Ostor AJK, Crisp AJ et al (2008) Hypovitaminosis D among rheumatology outpatients in clinical practice. Rheumatology 47:1348–1351CrossRefPubMed
67.
Sendur OF, Tastaba E, Turan Y et al (2008) The relationship between serum trace elements levels and clinical parameters in patients with fibromyalgia. Rheumatol Int 28:1117–1121CrossRefPubMed
68.
Rosborg I, Hyllén E, Lidbeck J et al (2007) Trace element pattern in patients with fibromyalgia. Sci Total Environ 385:20–27CrossRefPubMed
69.
Eisinger J, Plantamura A, Marie PA et al (1994) Selenium and magnesium status in fibromyalgia. Magnes Res 7(3–4)–285–288
70.
Schwarz MJ, Offenbaecher M, Neumeister A et al (2002) Evidence for an altered tryptophan metabolism in fibromyalgia. Neurobiol Dis 11:434–442CrossRefPubMed
71.
Torpy DJ, Papanicolaou DA, Lotsikas AJ et al (2000) Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6. A pilot study in fibromyalgia. Arthritis and Rheumatism 43(4):872–880
72.
Maes M, Verkerk R, Delmeire L et al (2000) Serotoninergic markers and lowered plasma branched-chain-amino acid concentrations in fibromyalgia. Psychiatry Res 97:11–20CrossRefPubMed
73.
74.
Caruso I, Puttini PS, Cazzola M et al (1990) Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 18:201–209PubMed
75.
Puttini PS, Caruso I (1992) Primary fibromyalgia syndrome and 5-HTP: a 90-day open study. J Int Med Res 20:182–189
76.
Nicolodi M, Sicuteri F (1996) Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis therapy. Adv Exp Med Biol 398:373–379PubMed
77.
Birdsall TC (1998) 5-Hydroxytriptohan: a clinically-effective serotonine precursor. Altern Med Rev 3(4):271–280PubMed
78.
Merchant RE, Carmack CA, Wise CM (2000) Nutritional supplementation with chlorella pyrenoidosa for patients with fibromyalgia syndrome: a pilot study. Phytother Res 14:167–173CrossRefPubMed
79.
Merchant RE, Andre CA, Wise CM (2001) Nutritional supplementation with chlorella pyrenoidosa for fibromyalgia syndrome: a double-blind, placebo-controlled, crossover study. J Musculoskelet Pain 9(4)
80.
Merchant RE, Andre CA (2001) A review of recent clinical trials of the nutritional supplement chlorella pyrenoidosa in the treatment of fibromyalgia, hypertension, and ulcerative colitis. Altern Ther Health Med 7(3):79–91PubMed
81.
Rossini M, Di Munno O, Valentini G et al (2007) Double-blind, multicenter trial comparing acetyl-l-carnitine with placebo in the treatment of fibomyalgia patients. Clin Exp Rheumatol 25(2):182–188PubMed
82.
Lister RE (2002) An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo Biloba extract in Fibromyalgia Syndrome. J Inter Med Res 30:195–199
83.
Olson GB, Savage S, Olson J (2000) The effects of collagen hydrolysat on symptoms of chronic fibromyalgia and temporomandibular joint pain. Cranio 18(2):135–141PubMed
84.
Bramwell B, Ferguson S, Scarlett N et al (2000) The use of ascorbigen in the treatment of fibromyalgia patients: a preliminary trial. Altern Med Rev 5(5):455–462PubMed
85.
Jacobsen S, Danneskiold-Samsoe B, Andersen RB (1991) Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 20(4):294–302
86.
Fetrow CW, Avila JR (2001) Efficacy of the dietary supplement S-adenosyl-L-methionine. Ann Pharmacother 35:1414–1425CrossRefPubMed
87.
Dykman KD, Tone C, Ford C et al (1998) The effects of nutritional supplements on the symptoms of fibromyalgia and chronic fatigue syndrome. Integr Physiol Behav Sci 33(1):61–71
88.
Werbach MR (2000) Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev 5(2):93–108PubMed
Metadata
Title
Fibromyalgia and nutrition, what do we know?
Authors
Laura-Isabel Arranz
Miguel-Ángel Canela
Magda Rafecas
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 11/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1443-0

Other articles of this Issue 11/2010

Rheumatology International 11/2010 Go to the issue

Case Report

Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy

Short Communication

Etanercept treatment in patients with rheumatoid arthritis on dialysis

Original Article

Clinical and radiological features of Takayasu’s arteritis patients in Jordan

Original Article

Systemic, secondary and infectious causes for cerebral vasculitis: clinical experience with 16 new European cases

Short Communication

The turnover of synovial T cells is higher than in T cells in the peripheral blood in persistent oligoarticular juvenile idiopathic arthritis

Letter to the Editor

IL-23 and IL-17 in ankylosing spondylitis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits